Why AbCellera Biologics Inc.’s (ABCL) Stock Is Up 10.84%
As of Thursday, September 17, AbCellera Biologics Inc.’s ABCL share price has surged by 10.84%, which has investors questioning if this is right time to sell.Michael Rose
Stock Evaluator: AbCellera Biologics Inc. (ABCL)
AbCellera Biologics Inc. ABCL
$12.66
0.03
0.24%
September 21, 2026 4:00:00 PM
EST
Volume: 4,421,861
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Life Sciences Tools & Services |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; Jazz Pharmaceuticals plc to develop T-cell engaging (TCE) multispecific antibodies; partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc.; and Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.
Commentary & Analysis
Why AbCellera Biologics Inc.’s (ABCL) Stock Is Up 10.24%
As of Thursday, September 17, AbCellera Biologics Inc.’s ABCL share price has surged by 10.24%, which has investors questioning if this is right time to sell.Omar Beirat
Why AbCellera Biologics Inc.’s (ABCL) Stock Is Down 5.32%
As of Friday, August 28, AbCellera Biologics Inc.’s ABCL share price has dipped by 5.32%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why AbCellera Biologics Inc.’s (ABCL) Stock Is Up 10.60%
As of Tuesday, August 25, AbCellera Biologics Inc.’s ABCL share price has surged by 10.60%, which has investors questioning if this is right time to sell.Michael Rose
Why AbCellera Biologics Inc.’s (ABCL) Stock Is Up 15.93%
As of Tuesday, August 25, AbCellera Biologics Inc.’s ABCL share price has surged by 15.93%, which has investors questioning if this is right time to sell.Jenna Brashear
Financial Summary
| Share Statistics | ABCL | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $4,102.4 | $3,615.8 | 64% |
|
| Shares Out (Mil) | 305.6 | 101.8 | 83% |
|
| Institutional Ownership | 55.2% | 89.5% | 37% |
|
| Float (Mil) | 220.9 | 71.1 | 76% |
|
| Beta | 1.32 | 1.19 | 76% |
|
| Avg Daily Volume (000s) | 4,491 | 904 | 91% |
|
| Price Change (52-week) |
168.2% | 90.5% | 97% |
|
| Growth | ABCL | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | (20.3%) | 7.8% | 2% |
|
| Net Income (5yr) | (26.4%) | (11.2%) | 16% |
|
| EPS (5yr) | (25.3%) | 2.5% | 10 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (15.1%) | (15.0%) | 51% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 3 | 5 | 4 | |
| Current EPS | ($0.173) | ($0.656) | ($0.715) | |
| Month Ago EPS | ($0.173) | ($0.656) | ($0.715) | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 1 | 0 | 0 | |
| Three Months Ago EPS | ($0.175) | ($0.650) | ($0.720) | |
| Year/Year Chg | (4.4%) | 33.9% | 74.1% | |
| Financials | ABCL | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $66 | $800 | 22% |
|
| Net Income (TTM) (Mil) | ($165) | ($32) | 8% |
|
| EPS (TTM) | ($0.546) | ($0.400) | 27% |
|
| Operating Cash Flow (TTM) (Mil) | ($95) | $47 | 6% |
|
| Net Cash Flow (TTM) (Mil) | $27 | $3 | 65% |
|
| Long-Term Debt (Q1) (Mil) | $130 | $230 | 46% |
|
| Enterprise Value (Q1) (Mil) | $3,688 | $3,471 | 57% |
|
| Valuation | ABCL | Industry Median |
Percentile (All Stocks) |
|
| P/B | 4.34 | 3.87 | 76% |
|
| P/E | na | 38.4 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 6.0 | na |
|
| Ratios | ABCL | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (198.9%) | 47.5% | 1% |
|
| Net Margin | (248.8%) | (6.0%) | 4% |
|
| ROA | (12.2%) | (4.8%) | 24% |
|
| ROE | (17.3%) | (7.9%) | 24% |
|
| Liabilities to Assets | 31.5% | 41.1% | 23% |
|
| F-Score | 5 | 5 | 50% |
|
AbCellera Biologics Inc. did not pass any screens on 9/21/2026.
